ARVINAS INC (ARVN:NASDAQ)
$7.42 -0.07 (-0.9346%)
Analysed ARVINAS INC (ARVN:NASDAQ) News Sources
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?
14-05-2026
yahoo.com
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
14-05-2026
yahoo.com
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
15-05-2026
yahoo.com
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
16-05-2026
yahoo.com
Arvinas Employees Give Back During Company-wide Impact Day
18-05-2026
yahoo.com
Arvinas to Present at Jefferies Global Healthcare Conference
29-05-2026
yahoo.com
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
04-06-2026
yahoo.com
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
05-06-2026
marketbeat.com
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
12-06-2026
yahoo.com
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
16-06-2026
yahoo.com
What is the current price of ARVINAS INC (ARVN:NASDAQ)?
The current price of ARVINAS INC (ARVN:NASDAQ) is $7.42.
ARVINAS INC (ARVN:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARVINAS INC (ARVN:NASDAQ) since the previous trading day is $-0.07.
ARVINAS INC (ARVN:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARVINAS INC (ARVN:NASDAQ) since the previous trading day is -0.9346%.
What is the most recent average sentiment score for ARVINAS INC (ARVN:NASDAQ)?
The most recent average sentiment score for ARVINAS INC (ARVN:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for ARVINAS INC (ARVN:NASDAQ)?
The most recent sentiment for ARVINAS INC (ARVN:NASDAQ) is .
SEC-8K** Filing Available For ARVINAS INC (ARVN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.